Massimiliano Camilli,Federico Ballacci,Valentina Alice Rossi,Antonio Cannatà,Luca Monzo,Nathan Mewton,Nicolas Girerd,Piero Gentile,Marco Marini,Massimo Mapelli,Andreas J Flammer,Nadia Aspromonte,Rocco Antonio Montone,Antonella Lombardo,Gaetano Antonio Lanza,Gianluigi Savarese,Frank Ruschitzka,Filippo Crea

Abstract:Aims: Iron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, regardless of anaemia status. Iron supplementation has been demonstrated to improve exercise capacity and quality of life in patients with HF with an ejection fraction <50% and ID. This survey aimed to provide data on real-world practices related to ID screening and management. Methods and results: We designed and distributed an online survey (23 questions) regarding ID screening and management in the HF setting. Overall, 256 cardiologists completed the survey (59.8% male, mostly between 30 and 50 years). The majority of physicians defined ID according to the most recent HF recommendations (98.4%) and reported screening for ID in more than half of their patients (68.4%). However, only 54.3% of the respondents performed periodic screening (every 6 months to 1 year). A total of 93.0% of participants prescribed and/or administered iron supplementation, using intravenous iron as the preferred method of administration (86.3%). After iron supplementation, 96.1% of the respondents reassessed ID, most frequently at 3-6 months (67.6%). Most physicians (93.8%) perceived ID as an underestimated comorbidity in HF. Cardiologists' age, training status, subspecialty and work setting (academic vs. non-academic hospitals) were associated with heterogeneity in the answers. Conclusions: The results of this survey highlight the need for more consistent strategies of ID screening and treatment for patients with HF.

Iron deficiency and supplementation in patients with heart failure: Results from the IRON-HF international survey